RT Journal Article
SR Electronic
T1 Monitoring the COVID-19 immunisation programme through a National Immunisation Management System – England’s experience
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.14.21263578
DO 10.1101/2021.09.14.21263578
A1 Tessier, Elise
A1 Stowe, Julia
A1 Tsang, Camille
A1 Rai, Yuma
A1 Clarke, Eleanor
A1 Lakhani, Anissa
A1 Makwana, Ashley
A1 Heard, Heather
A1 Rickeard, Tim
A1 Kirsebom, Freja
A1 Quinot, Catherine
A1 Lakhani, Shreya
A1 Power, Linda
A1 Edelstein, Michael
A1 Evans, Andy
A1 Ramsay, Mary
A1 Lopez-Bernal, Jamie
A1 White, Joanne
A1 Gower, Charlotte
A1 Andrews, Nick
A1 Campbell, Colin
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.14.21263578.abstract
AB In England, the National Immunisation Management System (NIMS) has been used to deliver COVID-19 vaccinations across England, monitor vaccine coverage, and assess vaccine effectiveness and safety.The NIMS was developed by a joint collaboration between a range of health and digital government agencies. Vaccinations delivered at large vaccination sites, pharmacies, hospitals and in primary care are entered on a point of care application which is verified using the unique NHS number in a centralised system containing information for everyone resident and registered with a GP in England. Vaccination details and additional data from hospital and GP records (such as priority groups) are sent to NHS Digital for data linkage. The NIMS constantly receives updated details from NHS Digital for all individuals and these data are provided to Public Health England (PHE) in a secure environment.PHE primarily use the NIMS for vaccine coverage, vaccine effectiveness and safety. Daily access to individual-level vaccine data has allowed PHE to rapidly and accurately estimate vaccine coverage and provide some of the world’s first vaccine effectiveness estimates.Other countries evaluating the roll-out and effect of COVID-19 vaccine programmes should consider a vaccine register or immunisation information system similar to the NIMS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no external funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Surveillance of covid-19 vaccination data is undertaken under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information (www.legislation.gov.uk/uksi/2002/1438/regulation/3/made) under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(3). Ethics approval also been approved by the head of research governance at Public Health EnglandAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request.